Claudia Harper

Claudia serves as Orna’s Senior Vice President, Preclinical Safety.

She is a recognized biotechnology leader who built and managed high-performing teams supporting preclinical laboratory operations for Amgen and Biogen, as well as preclinical development for Avrobio, where she was most recently Vice President of Preclinical Development. She is a relationship builder, proactive problem solver, and adaptable, a result-oriented team member with a demonstrated ability to identify, plan, and successfully execute cross-organizational project initiatives across R&D as well as develop and manage internal and external strategic alliances.

Her experience spans from being accountable for laboratory management, assay development, preclinical strategy, non-GLP, and GLP study design and analysis, and compliance to support drug discovery, early through mid-stage clinical drug development. Her industry exposure includes small molecules, replacement proteins, gene therapy, and biologics in lysosomal storage diseases, immunology, hemophilia, and neurology.

Claudia completed a Doctor of Veterinary Medicine (DVM) degree from Tufts University and a Postdoctoral Associate in Biomedical Research at the Division of Comparative Medicine at Massachusetts Institute of Technology (MIT). She is certified as a Diplomate of the American College of Laboratory Medicine (DACLAM) as well as Diplomate of the American Boards of Toxicology (DABT). She discovered, characterized, and named Helicobacter cetorum, co-authored peer-reviewed papers, published a book and several book chapters.